From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 7, 2008, Pages 871-882

  Nogueira Machado, José Augusto ^a   Martins Chaves, Miriam ^b  

^a Hospital Santa Casa de Belo Horizonte   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Advanced glycation end products; Advanced glycation end products receptor; Diabetes; Reactive oxygen species; Signalling pathways; Toll like receptors

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALT 946; AMIDE; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; DIACYLGLYCEROL; DIACYLGLYCEROL KINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (2 ACETAMIDOETHYL)HYDROZINECARBOXIMIDAMIDE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; PYRIDOXAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN;

CLINICAL TRIAL; COMPLEX FORMATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC PATIENT; DIABETOGENESIS; DRUG MECHANISM; ENZYME ACTIVITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MEDICAL LITERATURE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN RESTRICTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 48949116926     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.7.871     Document Type: Review

References (96)

1. Thomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanism. Ann NY Acad Sci 2002;967:43-8
2. Srivastva AK. High glucose-induced activation of protein kinase signalling pathway in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes. Int J Mol Med 2002;9:85-9
3. Nogueira-Machado JA, Lima E Silva FC, Lima E Silva R, et al. Effect in vitro of cyclic nucleotide-elevating agents on nitric oxide production by human granulocytes from type 2 diabetic patients. Diabetes Metab 2002;28:45-50
4. Nogueira-Machado JA, Lima E Silva FC, Cunha EP, et al. Modulation of the production of reactive oxygen species (ROS) by cAMP-elevating agents in granulocytes from diabetic patients: a Akt/PKB-dependent phenomenon. Diabetes Metab, 2006:32:331-5
5. Nogueira-Machado JA, Lima E Silva FC, Medina LO, et al. Modulation of the reactive oxygen species (ROS) generation mediated by cyclic AMP-elevating agents or interleukin 10 in granulocytes from type 2 diabetic patients (NIDDM): a PKA-independent phenomenon. Diabetes Metab 2003;29:533-7
6. Hii H, Daisuke K, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998;76:21-31
7. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55:498-510
8. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1998;19:257-67
9. Shikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemia damage. Nature 2000;404:787-90
10. Ques-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998;95:9220-5
11. Agopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alteration of vasomotor tone. J Clin Invest 1996;97:1916-23
12. Nes SA, O'Donnell VB, Wood J D, et al. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 1996;271:H1626-34
13. Pearson C, Ruef F, Madamanchi NR, et al. Stimulation of a vascular smooth muscle cell NADPH oxidase by thrombin: evidence that p47phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274:19814-22
14. Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase nox 1. Nature 1999;401:79-82
15. Pagano PJ, Clark JK, Cifuentes-Paganoi ME, et al. Localization of a constitutively active phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-8
16. Mohazzab-HKM, Kaminsk PM, Wolin MS. NADPH oxireductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-72
17. Nyshizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-14
18. Nishuzuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 1995;9:484-96
19. Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997;38:2711-9
20. Carrasco S, Mérida I. Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci 2007;32:27-36
21. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol 2001;87:1123-32
22. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63
23. Craven PA, Davidson CM, Derubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-74
24. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-9
25. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human vein endothelial cells - the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804
26. De Chaffoy DE, Courcelles D, Roevens P, et al. The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation. J Biol Chem 1989;264:3274-85
27. Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with anti-sense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007;282:22678-88
28. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10:142-8
29. Kin U, Tsilimingas N, Wendt M, Munzel T. Mechanism underlying endothelial dysfunction in diabetes mellitus: therapeutic implication. Treat Endocrinol 2003;2:293-304
30. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition. Am J Kidney Dis 2003;42:456-65
31. Long GE. Treatment of diabetic nephropathy with protein kinase C subtype beta inhibitor. Dev Ophthalmol 2007;39:157-65
32. Frank RN. Potential new medical therapies for diabetic retinopathy: Protein kinase inhibitor. Am J Ophthalmol 2002;133:693-8
33. Joy SV, Scates AC, Bearelly S, et al. Ruboxistaurin, a protein kinase C β inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005;39:1693-9
34. Adis International Limited. Ruboxistaurin: LY 333531. Drugs R&D 2007:8:193-9
35. Avignon A, Sultan A. PKC-B inhibition: a new therapeutic approach for diabetic complications. Diabetes Metab 2006;32:205-13
36. Wan Y. Termination of development of ruboxistaurin (Arxxant) for diabetic microvascular complications. Available online from: http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=584600 [Last accessed 22 May 2008]
37. Griending KK, Sorescu D, Ushio-Fukai M. NADPH-oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501
38. Vignais PV. The superoxide-generating NADPH-oxidase: structural aspects and activation mechanism. Cell Mol Life 2002;59:1428-59
39. Lassegue B, Clempus RE. Vascular NADPH-oxidase: specific features, expression and regulation. Am J Physiol Reg I 2003;285:R277-97
40. Tojo A, Asaba K, Onozato ML. Suppressing renal NADPH-oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 2007;11:1011-8
41. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanism of increased vascular superoxide production in human diabetes mellitus: role of NADPH-oxidase and endothelial nitric oxide synthase. Circulation 2002;105:1656-62
42. phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J 2000;14:1518-28
43. phox-based NADPH-oxidase in vascular smooth muscle. Biochem J 1998;329:653-7
44. Vecchione C, Arentini A, Mauno G, et al. Selective Rac-1 inhibition protects from diabetes-induced vascular injury. Circ Res 2006;98:218-25
45. Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statin against diabetes-induced oxidative stress. Diabetologia 2007;50:874-80
46. Benrahmoune M, Therond P, Abedinzadeh Z. The activation of superoxide radical with N-acetylcysteine. Free Radic Biol Med 2000:24:775-82
47. Stolk J, Hiltermann TJ, Dijkman JH, et al. Characteristics of the inhibition of NADPH-oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Biol 1994;11:95-102
48. Nakayama M, Inoguchi T, Sonta T, et al. Increased expression of NADP(H) oxidase in islet of animal models of type diabetes and its improvements by an AT1 receptor antagonists. Biochem Biophys Res Commun 2005;331:927-33
49. Brownlee M. Advanced glucosylation in diabetes and aging. Ann Rev Med 1995;46:223-34
50. Otevall A, Hulthe J, Rosengren A, et al. Autoantibodies against low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci 2001;101:523-31
51. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999;48:1-9
52. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complication. A new perspective on an old paradigm. Diabetes 1999;48:1-9
53. Corman B, Duriez M, Poitevin P, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998;95:1301-6
54. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-14
55. Kass DA. Getting better without AGE: new insight into the diabetic heart. Circ Res 2003;92:704-6
56. Zhang FL, Casey PJ. Protein prenylation: molecular mechanism and functional consequences. Ann Rev Biochem 1996;65:241-69
57. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-30
58. Degenhardt TP, Alderson NL, Arrimgton DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic-rat. Kidney Int 2002;61:939-50
59. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-45
60. Lo TW, Westwood ME, McLellan AC, et al. Binding and modifications of protein by methylglyoxal under physiologic conditions: a kinetic and mechanistic study with N--̇acetylarginine, N--̇acetylcysteine and bovine serum albumin. J Biol Chem 1994;269:32299-305
61. Ahmed MV, Thorpe SR, Baynes JW. Identification of N--̇carboxymethyllysine as a degradation product of fructosyl lysine in glycated protein. J Biol Chem 1986;261:4889-94
62. Rasheed Z, Ali R. Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci 2006;79:2380-8
63. Kurien B T, Hensley K, Bachamn M, et al. Oxidatively modified autoantigens in autoimmune disease. Free Radic Biol Med 2006;15:549-56
64. Wilson PW, Ben-Yehuda O, McNamara J, et al. Autoantibodies to oxidized LDL and cardiovascular risk: the Framinghan Offspring study. Atherosclerosis 2006;189:364-8
65. Ahmed E, Trifunovic J, Stegmavr, et al. Autoantibodies against modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke 1999;30:2541-6
66. Luoma JS, Karcinen A, Navanen O, et al. Autoantibodies against LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radic Biol Med 2205;39:1660-5
67. Lopez LR, Hurley BL, Simpson DF, et al. Oxidized low-density lipoprotein/ β2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann NY Acad Sci 2005;105:97-103
68. Malickova K, Skrha J, Janathkova I, et al. Antibodies against low density oxidized lipoprotein in type 2 diabetics. Epidemiol Microbiol Immunol 2004;53:131-5
69. Schmidt AM, Yan SD, Yan SF, et al. RAGE: a multiligand receptor serving as a progression factor amplifying the immune/inflammatory response. J Clin Invest 2001;108:949-55
70. Sugaya K, Fukagawa T, Matsumoto K, et al. Three genes in human MHC class III region near the junction with the class II gene for receptors of advanced glycosylation end products, PBX2 homebox gene and a notch homolog human counterpart of mouse mammary rumor gene int-3. Genomics 1994;23:408-19
71. Bierhaus A, Illmer M, Luther T, et al. Advanced glycation end products (AGE)-mediated of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262-71
72. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor/binding protein. J Biol Chem 1994;269:9889-97
73. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK and nuclear factor-κB in PBMNCs. Diabetes 2003;52:621-33
74. Taguchi A, Blood DC, Del Toro G, et al. Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases. Nature 2000;405:354-60
75. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effectives wound healing in diabetic mice. Am J Pathol 2001;159:513-25
76. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end products-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 2008;57:460-9
77. Tan AL, Forbes JM, Cooper ME. AGE, RAGE and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130-43
78. Coughlan MT, Cooper ME, Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signalling. Antioxid Redox Signal 2007;9:331-42
79. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005;12:562-672
80. Coughlan MT, Cooper ME, Forbes JM. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes? Ann NY Acad Sci 2005;1043:750-8
81. Soro-Paavonen, Forbes JM. Novel therapeutics for diabetic micro and macrovascular complications. Curr Med Chem 2006;13:1777-88
82. Stitt AW, Bucala R, Vlassara H, et al. Atherogenesis and advanced glycation: promotion, progression and prevention. Ann NY Acad Sci 1997;811:115-27
83. Buciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-28
84. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238-43
85. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-31
86. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vase Biol 2001;21:905-10
87. Buciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis apolipoprotein in E-null mice. Circulation 2002;106:2827-35
88. Wendt T, Buciarelli L, Qu W, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complication in diabetes. Curr Atheroscler Rep 2002;24:228-37
89. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variant of RAGE expressed in human vascular endothelial cells and pericytes and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109
90. Cheng C, Tsuneyama K, Kominami R, et al. Expression profiling of esRAGE in human organs. Mod Pathol 2005;18:1385-96
91. Devangelio E, Santilli F, Formoso G, et al. sRAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511-8
92. Forbes J, Thorpe S, Thallas-Bonke V, et al. Modulation of sRAGE by ACE-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-72
93. Lin L. RAGE on the Toll Road? Cell Mol Immunol 2006;3:351-8
94. Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res 2006;34:193-209
95. Hanson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19
96. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004;113:1641-50